Journal list menu
Export Citations
Download PDFs
ISSUE INFORMATION
EDITORIAL
Initiative of clinical single-cell biomedicine in clinical and translational medicine
- First Published: 20 January 2023
COMMENTARY
RAC-ing up tumour stemness: Disabled homolog 2 interacting protein and triple-negative breast cancer
- First Published: 19 February 2023

This commentary frames the novelty of Xiong et al (Clinical and Translational Medicine, 2022) in the context of the field. Research most directly related to DAB2IP's function as a tumor suppressor are briefly summarized and referenced, particularly in reference to breast cancer and the findings by Xiong et al related to RAC1.
Tumour-suppressive role and clinical application of DAB2IP in triple-negative breast cancer
- First Published: 30 December 2022
Defining cardiac fibrosis complexity and regulation towards therapeutic development
- First Published: 01 January 2023
Targeting the pentraxin 3/CD44 axis: A potential treatment for pulmonary fibrosis
- First Published: 05 February 2023
Mint3-targeted therapy: A novel therapeutic strategy for urothelial carcinoma
- First Published: 31 January 2023
Assessing neutrophil subsets in autoimmune disease: Moving away from relying on density?
- First Published: 03 February 2023
REVIEW ARTICLES
Gut microbiota intervention strategies using active components from medicinal herbs to evaluate clinical efficacy of type 2 diabetes – A review
- First Published: 07 February 2023
Dendritic cell-based immunotherapy: A potential therapeutic option for chronic Hepatitis B virus infection
- First Published: 12 February 2023

Dendritic cells (DCs) play a crucial role in initiating the adaptive immune response that could determine the outcome of Hepatitis B virus infection. The efficacy of DC-based immunotherapy may be improved via several strategies including treatment of interleukin-12, pDC-derived interferon (IFN)-α, monophosphoryl lipid A and IFN-γ, uric acid as well as blockade of B7 homolog 1. Besides, DCs with an engineered expression of HBV S-ecdCD40L, or pulsed with M1:HBcAg conjugates or transfection of recombinant plasmid pEGFP-N1-C (472-507)-ecdCD40L also showed improved efficacy.
Urine-based liquid biopsy in bladder cancer: Opportunities and challenges
- First Published: 21 February 2023

- (1) Development of liquid biopsy has great potential of clinical application in non-invasive detection of tumours.
- (2) Urine-based biomarkers or tests for clinical management in bladder cancer can be widely used for early detection, minimal residual, recurrence monitoring and therapeutic response.
- (3) Many challenges need to be overcomed in the discovery and validation studies of urine biomarkers for bladder cancer.
Progress of Actinidia chinensis Planch. root extract (acRoots) in cancer immunity
- First Published: 01 February 2023
Parkinson's disease fluid biomarkers for differential diagnosis of atypical parkinsonian syndromes
- First Published: 30 December 2022

Parkinson's disease (PD) and atypical parkinsonian syndromes (APS) are challenging to differentiate. Traditional biomarkers such as cerebrospinal fluid (CSF) alpha-synuclein, Aβ42, and tau cannot distinguish PD and APS patients with confidence. CSF protein misfolding cyclic amplification, real-time quaking-induced conversion, and neurofilament light chain are new-generation biomarkers that better differentiate PD from healthy controls. Attention has also moved to use non-CSF fluid biomarkers as they are less invasive.
RESEARCH ARTICLES
Hypoxia inducible factor-1 activator munc-18-interacting protein 3 promotes tumour progression in urothelial carcinoma
- First Published: 20 January 2023

Graphical Headlights
• Munc18-1-interacting protein 3 (Mint3) showed higher expression in urothelial carcinoma (UC) than normal urothelium.
• The expression level of Mint3 correlated with the malignancy of UC.
• Depletion of Mint3 suppressed a progression of UC in vivo.
• Mint3 inhibitor, Naphthofluorescein enhanced anti-tumour activity of gemcitabine.
SHORT COMMUNICATION
Blocking the action of NLRP3 inflammasome by inhaled ibuprofenate on pulmonary macrophages infected by SARS-CoV-2
- First Published: 23 January 2023